Rentschler Biopharma & Coriolis Pharma Announce Strategic Collaboration to Deliver End-to-End Biologics Development

Biologics development is becoming more complex. Modalities are evolving fast, regulatory expectations are higher than ever, and biopharma companies need partners who can move programs from discovery to commercial supply without friction.

To answer that growing market need, Rentschler Biopharma and Coriolis Pharma have announced a new strategic collaboration that connects formulation development with full-scale bioprocess development and manufacturing. The partnership aims to provide clients with a seamless, science-driven path from early R&D to commercial readiness.

Why This Collaboration Matters?

Biopharmaceutical programs increasingly require:

• Integrated workflows
• De-risked tech transfers
• Strong analytical and formulation expertise
• Reliable, scalable GMP manufacturing

By pairing their strengths, the two companies are positioning themselves as a unified solution for innovators navigating these challenges.

What Each Partner Brings to the Table?

Coriolis Pharma: Deep Scientific & Formulation Expertise

Coriolis provides:

• In silico + wet-lab formulation development
• Analytical and drug product development excellence
• Support across all development phases—from research to GMP
• Advanced characterization capabilities

Its scientific rigor and early-stage depth complement the needs of complex biologics programs.

Rentschler Biopharma: End-to-End Bioprocess Development & Manufacturing

Rentschler contributes:

• Proven bioprocess development for multiple biologic modalities
• GMP manufacturing from clinical to commercial scale
• Strong regulatory, project management, and partner-centric support
• Established expertise and reliability backed by decades in the industry

Their global footprint and operational maturity help ensure smooth progression into manufacturing and commercial supply.

Unified, End-to-End Solutions for Biologics Developers

Together, the companies will offer:

• A single interface for clients
• Faster movement from preclinical stages to market
• Reduced risks during tech transfer
• A connected scientific and operational approach
• Aligned project teams throughout the lifecycle

This is especially valuable as companies navigate increasingly complex biologic modalities—including next-gen proteins, viral vectors, and novel formulations.

Leadership Commentary

Rentschler Biopharma

CEO Benedikt von Braunmühl emphasized that the partnership strengthens their shared mission of advancing life-saving therapies. He highlighted the complementary expertise—bioprocess and manufacturing strength on Rentschler’s side paired with Coriolis’ scientific depth in formulation.

Coriolis Pharma

CEO Silvia Steyrer-Gruber noted that the collaboration aligns perfectly with Coriolis’ science-first partnership strategy. With both companies committed to innovation and client success, she underscored the potential to accelerate and de-risk complex biologics programs.

What Clients Can Expect?

Beginning December 2025, clients will gain access to the fully integrated platform. Key benefits include:

• Simplified development pathways
• Science-driven decisions from formulation to GMP
• Reduced program complexity
• Accelerated timelines

Both organizations operate in Germany and the United States, ensuring global reach with local market access.

About the Companies

Rentschler Biopharma

A leading CDMO offering bioprocess development, manufacturing, regulatory support, and consulting. With about 1,400 employees and a commitment to operational excellence, Rentschler enables reliable development and supply of high-quality biotherapeutics.

Coriolis Pharma

A globally recognized CRDO specializing in formulation development, analytical testing, and drug product services for a wide range of biological modalities. Coriolis recently expanded its global reach with new labs and U.S. headquarters in North Carolina.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!